Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

ALSUntangled found little objective evidence to support NuTech Mediworld’s stem cell treatment

Original source

NuTech MediworldALSUntangled · 5 May 2011 (opens in a new tab)

An ALSUntangled review found little objective information about the safety or effectiveness of NuTech Mediworld’s treatment for amyotrophic lateral sclerosis (ALS). The review described embryonic cell treatment, limited clinical documentation and unvalidated outcome reports. In one patient with available measurements, disease progression may have worsened after treatment.

Why this matters

This concerns people considering an expensive, unproven treatment at a stem cell clinic in New Delhi. The review does not show that the treatment benefits people with ALS and does not support changing treatment based on these reports.

Limitations and context

This was an expert review based on available records, clinic contacts, published literature searches and information from two patients, not a clinical trial. The clinic did not respond to the reviewers, and no detailed treatment protocol or reliable safety and efficacy data were available. The review was published in 2011, so it does not establish the clinic’s current practices.

Summarised by Compass 10 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?